860506 | C6 Ceramide (d18:1/6:0)

N-hexanoyl-D-erythro-sphingosine


Powder

Size SKU Packaging Price
10mg 860506P-10mg 860506P-10mg 1 x 10mg $148.10
5mg 860506P-5mg 860506P-5mg 1 x 5mg $85.90
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}

C6 Ceramide (d18:1/6:0)

C6 Ceramide (d18:1/6:0)

N-hexanoyl-D-erythro-sphingosine

Ceramide forms stable, fluid bilayers with cholesteryl phosphocholine, and this formulation has been shown to be more potent than solvent-delivered (DMSO) formulations of C6 Ceramide in inhibiting proliferation, inducing apoptosis, and disturbing calcium homeostasis.

Hygroscopic
No
Light Sensitive
No
Molecular Formula
C24H47NO3
Percent Composition
C 72.49%, H 11.91%, N 3.52%, O 12.07%
Purity
>99%
Stability
1 year
Storage Temperature
-20°C
CAS Number
124753-97-5
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
397.635
Exact Mass
397.356
Synonyms
N-(hexanoyl)-sphing-4-enine

Vaquer CC, Suhaiman L, Pavarotti MA, De Blas GA, Belmonte SA. Ceramide induces a multicomponent intracellular calcium increase triggering the acrosome secretion in human sperm. Biochim Biophys Acta Mol Cell Res. 2020 Mar 17:118704. doi: 10.1016/j.bbamcr.2020.118704. Epub ahead of print. PMID: 32194132.

PubMed ID: 32194132

Kao LP, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, Fox TE, Kester M, Loughran TP Jr, Abad JL, Fabrias G, Tan SF, Feith DJ, Claxton DF, Spiegel S, Fisher-Wellman KH, Cabot MC. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. J Lipid Res. 2019 Sep;60(9):1590-1602. doi: 10.1194/jlr.RA119000251. Epub 2019 Jul 30.

PubMed ID: 31363040

Morad SAF, MacDougall MR, Abdelmageed N, Kao LP, Feith DJ, Tan SF, Kester M, Loughran TP Jr, Wang HG, Cabot MC. Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen. Exp Cell Res. 2019 Aug 15;381(2):256-264. doi: 10.1016/j.yexcr.2019.05.021. Epub 2019 May 18.

PubMed ID: 31112736

Yamaguchi D, Imaizumi T, Yagi K, Matsumoto Y, Nakashima T, Hirose A, Kashima N, Nosaka Y, Hamada T, Okawa K, Nishiya Y, Kubo K. Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening. Sci Rep. 2019 May 23;9(1):7742. doi: 10.1038/s41598-019-43994-x.

PubMed ID: 31123329

Black AJ, Schilder RJ, Kimball SR. Palmitate- and C6 ceramide-induced Tnnt3 pre-mRNA alternative splicing occurs in a PP2A dependent manner. Nutr Metab (Lond). 2018 Dec 17;15:87. doi: 10.1186/s12986-018-0326-3. eCollection 2018.

PubMed ID: 30564278

Suhrland C, Truman JP, Obeid LM, Sitharaman B. Oxidized graphene nanoparticles as a delivery system for the pro-apoptotic sphingolipid C6 ceramide. J Biomed Mater Res A. 2019 Jan;107(1):25-37. doi: 10.1002/jbm.a.36474. Epub 2018 Nov 13.

PubMed ID: 30422374

Complexation of C6-Ceramide with Cholesteryl Phosphocholine – A Potent Solvent-Free Ceramide Delivery Formulation for Cells in Culture (2013). Pramod Sukumaran , Max Lönnfors , Otto Långvik, Ilari Pulli, Kid Törnquist, J. Peter Slotte.

PubMed ID: 23620740

Flowers, M., G. Fabrias, A. Delgado, J. Casas, J.L. Abad, and M.C. Cabot. (2012). C6-ceramide and targeted inhibition of acid ceramidase induce synergistic decreases in breast cancer cell growth. Breast Cancer Res Treat 133:447-58.

PubMed ID: 21935601